IMDX - Insight Molecular Diagnostics Inc. News

LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Targe

LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) w

Transcript: Insight Molecular Q2 2026 Earnings Conference Call

Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings cal

Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing a

Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform

Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtu

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House H

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript

CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analys

iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagn

NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Public

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transpl

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfoli

NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and t

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Eco

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidn

Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Che

NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journa

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to ei

Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American T

NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD

12 Health Care Stocks Moving In Friday's After-Market Session

Insight Molecular Q1 2026 Earnings Call Transcript

Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript

Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimat

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the anal

IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC re

Earnings Scheduled For May 13, 2026

Alpha Buying: Insider Conviction in High-Risk Biotech

12 Health Care Stocks Moving In Tuesday's Intraday Session

Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay

Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Im

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript

Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Re

Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to sh

Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the anal

IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasd

Earnings Scheduled For March 26, 2026

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IM

Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model

NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMD

12 Health Care Stocks Moving In Tuesday's Intraday Session

Lake Street Maintains Buy on Insight Molecular, Raises Price Target to $12

Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises

12 Health Care Stocks Moving In Wednesday's Intraday Session

Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share

Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today

Insight Molecular Outlines Commercial Gains, FDA De Novo Submission Plans For GraftAssureDx In 2026

GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-

Needham Maintains Buy on Insight Molecular, Raises Price Target to $9

Needham analyst Mike Matson maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the p

Insight Molecular Q3 EPS $(0.34) Misses $(0.21) Estimate, Sales $139.000K Miss $284.000K Estimate

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the anal

Earnings Scheduled For November 10, 2025

A Look at Insight Molecular's Upcoming Earnings Report

Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Moni

American Journal of Transplantation study positions GraftAssure as potentially essential in managing

Insight Molecular Launches 5,000-Patient Registry To Advance Kidney Transplant Rejection Test

Insight Molecular Diagnostics, Inc. (NASDAQ:IMDX), ("iMDx"), today announced a positive stra

Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx

iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyG

12 Health Care Stocks Moving In Tuesday's After-Market Session